Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
Clinical trial NCT04642937 · UNKNOWN
Trial details
- NCT number
- NCT04642937
- Sponsor
- OX2 Therapeutics
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-01
- Primary completion
- 2023-11-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.